secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2024-08-19T23:59:59+00:00
Accession:  0001193125-24-202551
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics promotes Arun Swaminathan to CEO effective Nov 1, 2024; Howard Berman becomes Executive Chairman
--------------------------------------------------------------------------------

- Arun Swaminathan, current CBO, promoted to CEO effective Nov 1, 2024; succeeds Howard Berman.
- Howard Berman resigns as CEO effective Oct 31, 2024, remains as Executive Chairman and director.
- Swaminathan appointed to Board of Directors as Class III director effective immediately.
- Swaminathan led Dr. Reddy's licensing transaction worth up to $700M; executed over $6B in deals.
- Company expects upcoming Alzheimer's data at CTAD24 on Oct 29, 2024; continues progress on COYA 302 in ALS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312524202551/0001193125-24-202551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312524202551/d861081d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-202551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer